Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects

Trial Profile

A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selumetinib (Primary) ; Paracetamol
  • Indications Astrocytoma; Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2018 Planned End Date changed from 2 Nov 2018 to 29 Oct 2018.
    • 17 Oct 2018 Planned primary completion date changed from 2 Nov 2018 to 29 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top